「yoshida1」の検索結果
67件：21～25件目を表示
もしかして
-
General Announcement: July 26, 2024 Senju Pharmaceutical Co., Ltd. Launch of Distribution of RET-700 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinaf
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726.pdf -
General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
General Announcement: July 26, 2024 Senju Pharmaceutical Co., Ltd. Launch of Distribution of RET-700 Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinaf
https://www.senju.co.jp/system/files/content_news/2024-07/ENG_20240726_0.pdf -
論文投稿実績 | 研究開発活動 | 千寿製薬株式会社
cretion in healthy subjects:A randomized, double-blind, placebo-controlled, crossover study Keisuke Yoshida1, Ryuji Takeda2, and Osamu Sakai1. 1 Senju Pharmaceutical, Co., Ltd., 2 Kansai University of...
https://www.senju.co.jp/rd/thesis/ -
Publications | Research & Development | SENJU Pharmaceutica
cretion in healthy subjects:A randomized, double-blind, placebo-controlled, crossover study Keisuke Yoshida1, Ryuji Takeda2, and Osamu Sakai1. 1 Senju Pharmaceutical, Co., Ltd., 2 Kansai University of...
http://www.senju.co.jp/english/rd/thesis/